Dallas, TX & The Netherlands — October 17, 2025 — Trained Therapeutix, Inc., a biotech company training immunity at its origin with nanomedicines, today announced that Joost Kreijtz, PhD, has been appointed Chief Executive Officer of Trained Therapeutix (NL), the company’s Dutch subsidiary and operational arm, effective immediately.
“Joost has been the operational backbone of our Dutch organization and a key architect of our development strategy,” said Leighton Durham, CEO of Trained Therapeutix, Inc. “His track record advancing programs from discovery through IND-enabling work and into the clinic, coupled with deep hands-on leadership across R&D, nonclinical, CMC, and early clinical execution, makes him the right leader for our R&D innovation hub.”
Dr. Kreijtz has served as Trained Therapeutix’s Chief Development Officer since 2021, managing the Dutch R&D site and leading the strategy and execution for nonclinical pharmacology, safety, PK, and CMC activities, while shaping clinical development plans and CRO partnerships. Prior to Trained Therapeutix, he led and advised multiple antibody and vaccine programs through nonclinical, regulatory, and early clinical milestones. Dr. Kreijtz received his PhD in immunovirology from Erasmus University Medical Center.
“I’m honored to lead Trained Therapeutix (NL),” said Dr. Joost Kreijtz. “Our teams in the Netherlands and the U.S. are united by a clear mission: to translate our nanomedicine platform into meaningful therapies for patients. I look forward to accelerating our path to first-in-human studies and building the partnerships that will carry our programs through clinical proof-of-concept.”
As CEO of Trained Therapeutix (NL), Dr. Kreijtz will oversee all Netherlands-based operations and development activities for the company’s pipeline, working closely with the executive team and the Board of Directors of Trained Therapeutix, Inc.
About Trained Therapeutix
Trained Therapeutix is a biotechnology company developing a new class of therapeutics with nanomedicines that train immunity at its origin with applications in oncology and immune-mediated diseases. Trained Therapeutix (NL) is the company’s Dutch subsidiary and operational hub for research and development.
